American College of Rheumatology

Obinutuzumab for Treatment of Lupus Nephritis Shows Promise in Phase 2 Trial

November 15, 2019

Article

Richard Furie, MD, chief of the division of rheumatology with Norwell Health, discusses the results of a phase 2 trial examining obinutuzumab for lupus nephritis.

Philip Mease, MD: Treatment Options for Psoriatic Arthritis

November 15, 2019

Article

Philip Mease, MD, director of rheumatology research at the Swedish Rheumatology Research Group, discusses the current state of treatments for psoriatic arthritis.

Trial Data Indicates Golimumab Improves Quality of Life in Psoriatic Arthritis

November 14, 2019

Article

Elaine Husni, MD, discusses the results of a trial she led examining quality of life changes in psoriatic arthritis patients receiving golimumab over a 1-year period.

Safety Profile of Filgotinib Highlighted in Pooled Phase 3 Analysis

November 14, 2019

Article

John Sundy, MD, PhD, senior vice president of Inflammation and Respiratory Disease with Gilead Sciences, discusses the results of a pooled safety analysis examining phase 3 studies of filgotinib.

Clinical Trial Data Supports Teprotumumab for Treating Thyroid Eye Disease

November 14, 2019

Article

Raymond Douglas, MD, PhD, discusses teprotumumab and its potential for treating thyroid eye disease.

Hydroxychloroquine Could Cut Recurrence of Congenital Heart Block in Half

November 14, 2019

Article

Peter Izmirly, MD, discusses the results of a trial he led examining the possible reduction in recurrence of congenital heart block from treatment with hydroxychloroquine at ACR 2019.

Q&A with Leonard Calabrese, DO: Vaccinating in Immunocompromised Patients

November 14, 2019

Article

Renowned infectious disease expert Leonard Calabrese, DO, professor of medicine at the Cleveland Clinic Lerner College of Medicine, takes part in a Q&A on vaccinations in immunocompromised patient populations.

Upadacitinib Shows Promise for Ankylosing Spondylitis in SELECT-AXIS 1

November 14, 2019

Article

Aileen Pangan, MD, executive medical director of Immunology with AbbVie, discusses the results of the SELECT-AXIS 1 trial and what it indicates about upadacitinib as a treatment for ankylosing spondylitis.

Phase 2b Trial Shows Telitacicept Safe, Effective for Treatment of Lupus

November 14, 2019

Article

Jianmin Fang, PhD, CEO and founder of Remegen Ltd., discusses the results of a phase 2b trial exmaining the use of telitacicept for the treatment of SLE.

Lorecivivint a Potential Novel Treatment for Knee Osteoarthritis

November 13, 2019

Article

Yusuf Yazici, MD, chief medical officer of Samumed, discusses SM04690(Lorecivivint) at ACR 2019.

x